NIFTY 50
22,828.55 (1.92%)
NIFTY IT
32,740.85 (0.69%)
NIFTY AUTO
20,548.65 (2.03%)
NIFTY FINANCIAL SERVICES
24,555.55 (1.75%)
NIFTY BANK
51,002.35 (1.52%)
NIFTY REALTY
790.15 (1.26%)
NIFTY ENERGY
32,411.10 (2.70%)
NIFTY METAL
8,168.30 (4.09%)
NIFTY FMCG
55,741.10 (0.86%)
NIFTY HEALTH CARE
13,326.65 (1.53%)
NIFTY PHARMA
20,461.90 (2.43%)
NIFTY MEDIA
20,461.90 (2.43%)
Platforms
Mobile Application
Web Trading
Desktop Application
Insights
Research
Videos
Markets
Equity
Derivatives
IPO
Other Markets
Corporate Information
Pricing
Support
Login
Open an Account
Home
Platform
Insights
Research
Markets
Pricing
Support
Login
Open an Account
Trend of Stock Market
A trend is the broad upward or downward movement of a stock's price over time
Forthcoming IPO
Open Issues
Closed Issue
Top Gainers / Losers
52 Weeks High/ Low
Value / Volume Toppers
Get Quotes
Nifty Futures
Top Traded Quantity
Top Traded Value
Derivative Summary
Daily Settlement Price
List Of Underlying
Put Call Ratio
FII Statistics
Most Active Contract
All Index Futures
Top Gainers
Top Losers
Highest In OI
Lowest In OI
Increase In OI
Decrease In OI
Most Active Calls
Most Active Put
Top Gainers
Top Losers
Highest In OI
Lowest In OI
Increase In OI
Decrease In OI
Forthcoming Issues
Open Issues
Closed Issue
World Indices
ADR Prices
MF Investment
FII Investment
Get Quotes
Company Snapshot
Company Background
Board of Directors
Directors Reports
Profit & Loss
Balance Sheet
Quarterly Results
Shareholding Pattern
Key Financial Ratios
Mutual Fund Holdings
Peer Comparison
Technical Chart
Company News
Change Company Name
Aurobindo Pharma Ltd
Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
524804
ISIN Demat
INE406A01037
Book Value
335.47
NSE Symbol
AUROPHARMA
Dividend Yield (%)
0.42
Market Cap (
₹
Cr.)
63,430.78
P/E
33.09
EPS
32.72
Face Value
1
Date
Headline
11-Apr-25
USFDA inspects Aurobindo Pharma's Raleigh Plant in North Carolina
09-Apr-25
CuraTeQ Biologics completes Phase 1 study of denosumab biosimilar, BP16
21-Mar-25
Aurobindo Pharma update on preferential issue by Curateq Biologics
19-Mar-25
Apitoria Pharma's Unit-V completes USFDA inspection
05-Mar-25
Auro Vaccines terminates license agreement with Hilleman Laboratories Singapore
28-Feb-25
Aurobindo Pharma acquires 80% stake in Tergene Biotech
20-Feb-25
USFDA inspects Aurobindo Pharma USA Inc.'s warehouse facility in New Jersey
06-Feb-25
Board of Aurobindo Pharma approves acquisition of 80% stake in Tergene Biotech
28-Jan-25
Apitoria Pharma's Unit 2 completes USFDA inspection
17-Jan-25
Aurobindo Pharma to table results
Prev
1
2
3
Next